博瑞医药：关于BGM1812注射液获美国FDA药品临床试验批准的公告

Core Viewpoint - The company, Borui Pharmaceutical, has received approval from the U.S. FDA to initiate Phase I clinical trials for BGM1812 injection aimed at treating overweight or obesity [2] Group 1 - The announcement was made on the evening of September 29 [2] - The approval marks a significant step for the company in the development of treatments for obesity [2]